Victor Sandor
Director/Board Member chez MERUS N.V.
Fortune : 261 969 $ au 31/03/2024
Profil
Victor Sandor is an Independent Non-Executive Director at Merus NV, ADC Therapeutics SA, Prelude Therapeutics, Inc., Kymera Therapeutics, Inc., and Istari Oncology, Inc. He previously worked as the SVP-Global Clinical Development at Incyte Corp., Chief Medical Officer at Array BioPharma, Inc., and Chief Medical Officer-Oncology & VP at Biogen Idec, Inc. He holds a doctorate degree from McGill University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ADC THERAPEUTICS LTD
0,07% | 01/02/2024 | 58 345 ( 0,07% ) | 261 969 $ | 31/03/2024 |
MERUS N.V.
-.--% | 08/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
| 16/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 | |
| 15/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Victor Sandor
| Sociétés | Poste | Début |
|---|---|---|
| MERUS N.V. | Director/Board Member | 12/06/2019 |
| ADC THERAPEUTICS SA | Director/Board Member | 27/04/2020 |
| PRELUDE THERAPEUTICS INCORPORATED | Director/Board Member | 01/05/2020 |
| KYMERA THERAPEUTICS, INC. | Director/Board Member | 03/11/2022 |
Istari Oncology, Inc.
 Istari Oncology, Inc. BiotechnologyHealth Technology Istari Oncology, Inc. operates as a clinical-stage biotechnology company. It focuses on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. Its core technology assets are PVS-RIPO, a prototypic oncolytic recombinant polio virus vaccine, and a series of antibody-drug conjugates comprising antibodies or antibody fragments to a variety of oncology targets. The company was founded by Darell D. Bigner and Matthias Gromeier in 2016 and is headquartered in Research Triangle Park, NC. | Director/Board Member | 01/07/2019 |
Anciens postes connus de Victor Sandor
| Sociétés | Poste | Fin |
|---|---|---|
| INCYTE CORPORATION | Chief Tech/Sci/R&D Officer | 01/09/2019 |
| ARRAY TECHNOLOGIES, INC. | Chief Tech/Sci/R&D Officer | 01/08/2019 |
Biogen Idec, Inc. (North Carolina)
 Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The private company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016. | Corporate Officer/Principal | 01/09/2014 |
Formation de Victor Sandor
| McGill University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| INCYTE CORPORATION | Health Technology |
| MERUS N.V. | Health Technology |
| ADC THERAPEUTICS SA | Health Technology |
| PRELUDE THERAPEUTICS INCORPORATED | Health Technology |
| KYMERA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Array BioPharma, Inc.
 Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |
Biogen Idec, Inc. (North Carolina)
Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The private company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016. | Health Technology |
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Istari Oncology, Inc. operates as a clinical-stage biotechnology company. It focuses on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. Its core technology assets are PVS-RIPO, a prototypic oncolytic recombinant polio virus vaccine, and a series of antibody-drug conjugates comprising antibodies or antibody fragments to a variety of oncology targets. The company was founded by Darell D. Bigner and Matthias Gromeier in 2016 and is headquartered in Research Triangle Park, NC. | Health Technology |
